Home   Categories   Grid

Subscribe Now

Blood test for minimal residual disease in cancer patients will be accelerated by $35m Inivata financing

Blood test for minimal residual disease in cancer patients will be accelerated by $35m Inivata financing

Blood test for minimal residual disease in cancer patients will be accelerated by $35m Inivata financing

08 February 2021

It raises Series C financing to $60m


Sano Genetics to accelerate long Covid research after £2.5m seed funding

Sano Genetics to accelerate long Covid research after £2.5m seed funding

Sano Genetics to accelerate long Covid research after £2.5m seed funding

28 January 2021

The Cambridge-based digital health technology company will supply at-home DNA testing kits for 3,000 patients.

1

Astex and Taiho strike further oncology licensing deal with MSD

Astex and Taiho strike further oncology licensing deal with MSD

Astex and Taiho strike further oncology licensing deal with MSD

21 January 2021

It focuses on small molecule SHP2 inhibitor candidates.


Sanofi to acquire Babraham Research Campus-based Kymab in deal worth up to $1.45bn

Sanofi to acquire Babraham Research Campus-based Kymab in deal worth up to $1.45bn

Sanofi to acquire Babraham Research Campus-based Kymab in deal worth up to $1.45bn

15 January 2021

The deal is expected to be completed in the first half of 2021.


Light Blue Fibre’s full-fibre network enables high-performance computing in Cambridge region

Light Blue Fibre’s full-fibre network enables high-performance computing in Cambridge region

Light Blue Fibre’s full-fibre network enables high-performance computing in Cambridge region

14 January 2021

It is designed to handle the massive data demands for the life science industry and explosion in artificial intelligence.


Sosei Heptares to regain rights from AbbVie to programmes targeting neurological diseases

Sosei Heptares to regain rights from AbbVie to programmes targeting neurological diseases

Sosei Heptares to regain rights from AbbVie to programmes targeting neurological diseases

05 January 2021

They were initially licensed to Allergan.


Mogrify strengthens IP position for cell conversion technology

Mogrify strengthens IP position for cell conversion technology

Mogrify strengthens IP position for cell conversion technology

28 December 2020

The Cambridge Science Park company has also extended the method.


Biofidelity moves to larger Cambridge Science Park HQ and appoints Dr Robert Osborne as COO

Biofidelity moves to larger Cambridge Science Park HQ and appoints Dr Robert Osborne as COO

Biofidelity moves to larger Cambridge Science Park HQ and appoints Dr Robert Osborne as COO

17 December 2020

The cancer diagnostics company is preparing to launch its first product.


Crescendo Biologics expands collaboration with Takeda

Crescendo Biologics expands collaboration with Takeda

Crescendo Biologics expands collaboration with Takeda

16 December 2020

It has met its sixth technical milestone.


Why AstraZeneca is acquiring rare disease specialist Alexion for $39bn

Why AstraZeneca is acquiring rare disease specialist Alexion for $39bn

Why AstraZeneca is acquiring rare disease specialist Alexion for $39bn

14 December 2020

The company will set up a new rare disease unit in Boston.


Why investors cannot get enough of the Cambridge tech market

Why investors cannot get enough of the Cambridge tech market

Why investors cannot get enough of the Cambridge tech market

09 December 2020

An interview with Stewart Frost, of J P Morgan Private Bank, on the outlook from investors.

1

Artios Pharma strikes stunning precision cancer drug deal worth up to $6.9bn with Merck KGaA

Artios Pharma strikes stunning precision cancer drug deal worth up to $6.9bn with Merck KGaA

Artios Pharma strikes stunning precision cancer drug deal worth up to $6.9bn with Merck KGaA

03 December 2020

The companies aim to create a global powerhouse in DNA damage repair space.


OKRA Technologies unveils ValueScope to predict new drug prices years before launch

OKRA Technologies unveils ValueScope to predict new drug prices years before launch

OKRA Technologies unveils ValueScope to predict new drug prices years before launch

03 December 2020

The AI-powereed system has been shown to be more than 90 per cent accurate.


Cerevance buoyed by postive clinical trial results for schizophrenia compound

Cerevance buoyed by postive clinical trial results for schizophrenia compound

Cerevance buoyed by postive clinical trial results for schizophrenia compound

18 November 2020

The Cambridge Science Park company is using unique technology to target brain diseases.


Sareum welcomes revised deal between Sierra and CPF on checkpoint inhibitor

Sareum welcomes revised deal between Sierra and CPF on checkpoint inhibitor

Sareum welcomes revised deal between Sierra and CPF on checkpoint inhibitor

17 November 2020

The agreement reduces potential milestone payments, but expedite its development.


Genome origami of Covid-19 virus unravelled by University of Cambridge researchers

Genome origami of Covid-19 virus unravelled by University of Cambridge researchers

Genome origami of Covid-19 virus unravelled by University of Cambridge researchers

13 November 2020

Gurdon Institute work could prove key to developing new drugs against SARS-CoV-2.


AstraZeneca encouraged by rise in sales and profits despite pandemic disruption

AstraZeneca encouraged by rise in sales and profits despite pandemic disruption

AstraZeneca encouraged by rise in sales and profits despite pandemic disruption

12 November 2020

The company has also announced a number of approvals.


Finalists in the 2020 Cambridge Independent Science and Technology Awards revealed

Finalists in the 2020 Cambridge Independent Science and Technology Awards revealed

Finalists in the 2020 Cambridge Independent Science and Technology Awards revealed

11 November 2020

The shortlist of companies and individuals across 14 categories has been unveiled.


Congenica raises $50m to power global genomic medicine revolution

Congenica raises $50m to power global genomic medicine revolution

Congenica raises $50m to power global genomic medicine revolution

11 November 2020

The funding will help it expand its product portfolio and reach more health systems.


Don’t miss our 9-page celebration of the finalists in the Cambridge Independent Science and Technology Awards 2020

Don’t miss our 9-page celebration of the finalists in the Cambridge Independent Science and Technology Awards 2020

Don’t miss our 9-page celebration of the finalists in the Cambridge Independent Science and Technology Awards 2020

10 November 2020

From biotechs to AI companies, cleantechs to start-ups, an astonishing array of talent is on show.


This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More